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Abstract
The purpose of this chapter is a focused analysis and review of rare thyroid malignan‐
cies  including  anaplastic  thyroid  cancer  (ATC),  medullary  thyroid  cancer  (MTC),
primary thyroid lymphoma (PTL), and primary thyroid sarcoma (PTS). The focus will
be on the epidemiology, risk factors, workup, and a contemporary review of manage‐
ment of these rare entities.
Keywords: anaplastic thyroid cancer, medullary thyroid cancer, thyroid lymphoma,
thyroid sarcoma
1. Introduction
The majority of thyroid neoplasms are well-differentiated lesions that have been extensive‐
ly studied and reported in the literature with regard to diagnosis and management [1, 2].
While  most  patients  with  thyroid  malignancy  typically  fall  in  to  the  above-mentioned
category, few patients may carry diagnoses of rare thyroid cancers that are not as widely
researched.  Owing  to  the  dearth  of  literature  on  these  rare  thyroid  malignancies,  the
consensus for management is often unclear and highly debated. As head and neck oncolo‐
gists should be well versed in the treatment options for these uncommon malignancies, this
chapter seeks to coalesce the literature in hopes of providing practitioners with an over‐
view of these challenging pathologies. The chapter will focus on the analysis of anaplastic
thyroid cancer (ATC), medullary thyroid cancer (MTC), primary thyroid lymphoma (PTL),
and primary thyroid sarcoma (PTS). In the following sections, each of these entities will be
discussed  beginning  with  epidemiology  and  risk  factors  progressing  to  work  up  and
management.
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2. Anaplastic thyroid cancer
ATC is among the most aggressive and uniformly fatal malignancies afflicting the human
species. It is extremely rare, comprising approximately 2–5% of all thyroid malignancies [3–
5]. The annual incidence of ATC is one to two cases per million. The majority of patients, greater
than 90%, are over the age of 50 [5–7]. Females are more commonly affected than males, with
a comparison ratio of approximately 1.5:1 [6, 8]. A large majority of ATC occurs in conjunction
with other thyroid cancers and is theorized to be a degeneration of well-differentiated
carcinomas [1, 8].
Few patients survive beyond 6 months after initial presentation, with a median survival of 2–
12 months [1, 3, 4, 6, 9]. At present, it is reported that more than 50% of patients with ATC have
distant metastases [10]. Patients typically present with a rapidly enlarging neck mass, often
stating that the neck mass was stable for a significant period of time before the period of rapid
growth. Not uncommonly, patients complain of pain, dysphonia, and difficulty breathing as
the mass grows and begins to invade the laryngopharyngeal framework [2]. Death from ATC
is typically caused by compression of the great vessels, namely the superior vena cava, or
asphyxiation from airway compromise [2].
As with any rapidly enlarging neck mass, airway stability is of primary importance and a stable
airway should be established even prior to diagnosis if the patient is unstable. In the event the
patient has a stable airway, following thorough examination including nasopharyngolaryngo‐
scopy, imaging should be obtained to evaluate the extent and radiographic characteristics of
the mass. Computed tomography (CT) is typically the initial imaging study of choice, however,
magnetic resonance imaging (MRI) can be obtained to determine the extent of soft tissue and
cartilage involvement. Following imaging, tissue diagnosis can be established with fine-needle
aspiration (FNA); however, at times a larger tissue sample may be needed to rule out lym‐
phoma [2]. Pathology of ATC typically shows gross macroscopic involvement of surrounding
tissue along with areas of florid necrosis. A population of undifferentiated cells is typically
seen, along with a heterogeneous population of polygonal, spindle, and giant cells. As cells
are poorly differentiated, no thyroglubin production or thyroid hormone receptors are found
on further evaluation [1]. After a diagnosis of malignancy is established, practitioners may opt
to pursue a fludeoxyglucose (18F-FDG) positron emission tomography (PET) scan or whole
body CT scan to evaluate for metastases. Staging of ATC is based on its extension from the
thyroid gland and distal metastases. All lesions are considered stage 4; stage 4A for lesions
within the thyroid gland without distal spread, stage 4B for lesions that have grown outside
the thyroid without distal spread, and stage 4C for any lesion that has distal metastases [11].
The management of ATC poses a number of challenges for the practitioner owing to the
advanced nature of the malignancy at diagnosis, short survival time, and often severe
functional impairment. Of paramount importance is an understanding of the patient’s desires
and the goals of care. Treatment options include radiation, surgery, chemotherapy, or a
combination. Commonly, patients require tracheostomy and enteral feeding support with a
gastrostomy tube [2, 6]. Routine tracheostomy is not advocated and the decision is highly
based on the patients desire to undergo a surgical airway procedure in lieu of potential
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changes in the quality of life [12, 13]. Chemotherapeutic regimens have not been uniformly
accepted and as such, there is no standard regimen. In recent studies, however, there have
been promising results with newer drug modalities. The combination of carfilzomib, a
proteasome inhibitor, and CUDC-101, a histone deacetylase, have been shown to induce
apoptosis in anaplastic thyroid cancer cells [14]. Another recent study has shown positive
results through the use of doxorubicin nanospheres combined with extracorporeal shock
wave therapy [15].
The role of surgery is controversial. In conjunction with the American Thyroid Association,
Smallridge et al. report that surgery can be considered with locoregional disease; however,
given the lack of survival benefit, they recommend against tumor debulking [16]. Disease
extending beyond the thyroid gland has typically represented unresectable disease [17–22].
In a recent study by Brown and Ducic, 16 patients with extrathyroidal ATC were evaluated
for long-term survival following complete surgical resection. These patients had stage 4B ATC
without evidence of distal metastases, and no disease extension beyond the carotid arteries.
Twelve patients required total laryngectomy, four required tracheal resection, and six required
cervical esophagectomy. Twelve out of 16 patients also required bilateral complete neck
dissection for clinically evident disease. Postoperatively, surgical patients underwent external
beam radiation. Of the 16 patients that underwent surgery with adjuvant radiation, 50% had
long-term disease free survival ranging from 9 months to 8 years. Six patients died from
metastatic disease while one died from a myocardial infarction. Based on their findings, Brown
and Ducic believe that specific patients with extrathyroidal ATC that does not extend lateral
to the carotid artery and without distal metastases may be suitable surgical candidates for
complete resection followed by radiation therapy [23].
Regardless of treatment modality chosen, resectability of locoregional cancer, localized
intrathyroidal disease, and absence of distal metastases are associated with a more favorable
prognosis [24–26].
Anaplastic thyroid cancer is an aggressive disease with a high mortality rate. Early detection
with thoughtful planning involving the patient’s family is the cornerstone of managing this
challenging malignancy.
3. Primary thyroid sarcoma
PTS is an extremely rare entity with an incidence no higher than 1.5% [27–29]. The rarity of
PTS has led to a substantial dearth of literature and the majority of information is based on
scattered case reports in the literature, along with several review papers. PTS is a general term
for all types of thyroid sarcoma; however, specific entities include angiosarcoma, heman‐
gioendothelioma, fibrosarcoma, leiomyosarcoma, fibrous histiocytoma, and several others.
Patients are typically between the ages of 60 and 80 years and do not possess any other specific
risk factors for this entity. Presenting complaints center on a thyroid nodule without any
specific signs or symptoms unless they have advanced disease [29]. Diagnosis for PTS is similar
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to other thyroid nodules, centered on ultrasound imaging followed by FNA. On ultrasound,
these lesions have a hypohyperechoic pattern in comparison to normal thyroid tissue. As the
pattern is nonspecific, it may raise suspicion for PTS but by no means is pathognomonic [30].
It is important for the practitioner to realize that certain subsets of sarcoma, such as angiosar‐
coma, can often have similar pathologic findings as other thyroid malignancies. In a study by
Bayir et al., it was reported that angiosarcoma can be mistaken as ATC due to similar pathologic
findings; however, angiosarcoma tends to bleed more significantly than ATC and often leaves
a hematoma at the FNA site [31]. Although treatment is based on surgery with postoperative
radiation for advanced disease, there is no standard protocol for treatment given the rare
nature of this disease.
In a contemporary review, Surov et al. examined the PTS literature and evaluated the cases of
142 patients with PTS. They reported a slight male preponderance and found that the majority
of patients, approximately 70%, did not present with distal metastases at presentation. Patients
typically had a painless goiter, and a small subset of patients had dyspnea and dysphagia
indicating advanced disease [30]. Of their population, approximately 20% of lesions were
angiosarcoma, 15% were malignant hemangioendothelioma, followed by smaller percentages
of fibrous histiocytoma, leiomyosarcoma, and fibrosarcoma. Leiomyosarcoma and malignant
histiocytoma were reported to be more likely to infiltrate the trachea or esophagus compared
to the other subtypes [30].
Fibrosarcoma patients were more likely to present with regional disease while leiomyosarco‐
ma and angiosarcoma patients were more likely to present with distal disease. Patients with
distal metastases primarily involved the lung [30]. In their review, 75 patients were treated
with surgery as single modality, while 53 had surgery with adjuvant chemo-radiation. One
patient had only radiation, two had just chemotherapy, and four had chemo-radiation without
surgery. During the follow-up period of 0.5–120 months (median 7 months), 31% of patients
were living while the remainder died or were lost to follow-up [30].
As mentioned previously, due to the lack of cohesive literature, there have been no studies
reporting the overall 5-year survival or disease free survival of PTS as a group. One study
reported a 33% 5-year survival for angiosarcoma of the thyroid and noted that patients present
at a late stage [32]. While this statistic may not be applicable to other subtypes of sarcoma, the
practitioner must understand that given the possibility of this rare malignancy and its tendency
for locally aggressive behavior, any thyroid nodule with suspicious features should be imaged
and biopsied in a timely fashion.
4. Primary thyroid lymphoma
PTL comprises 1–5% of all thyroid malignancies with women more commonly affected than
men [33, 34]. The disease typically affects individuals between the ages of 50 and 80, and is
rarely found in those younger than 40 years of age [35, 36]. Carrying a diagnosis of Hashimoto’s
thyroiditis is a major risk factor for PTL. Studies by Holm and Kato report a 67–80-fold
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increased risk of PTL in patients with Hashimoto’s thyroiditis [37, 38]. In a 2015 study by Chai
et al., 87% of patient with PTL had Hashimoto’s [39].
Patients typically present with a painless enlarging neck mass, often in the setting of a known
autoimmune thyroiditis. Adenopathy can be associated with the primary complaints as well
[40]. Complaints of dysphagia, dyspnea, and hoarseness are uncommon, and signify advanced
disease with compressive symptoms or invasion of the recurrent laryngeal nerve [2]. Only an
estimated 10% of patients present with constitutional symptoms such as fever, weight loss,
and night sweats [5]. Following thorough history and physical examination, thyroid studies
can be obtained followed by ultrasound and fine needle aspiration if indicated. FNA by itself
may yield inconclusive information and as such, either ultrasound guided FNA or open biopsy
is recommended [2, 41, 42].
PLT is a broad term encompassing multiple pathologies. B-cell non-Hodgkin’s lymphoma
(NHL) is by far the most common cell line in PTL; T-cell lymphoma, plasmacytoma, and
Hodgkin’s lymphoma have been reported but are exceedingly rare [42, 43]. The three main
subtypes of B-cell NHL are mucosal associated lymphoid tissue (MALT) lymphoma, diffuse
large B-cell lymphoma (DLBCL), and a mixed variant of DLBCL and MALT [39]. MALT
lymphoma is generally of low grade and indolent growth while DLBCL is high grade with
aggressive growth. The mixed variant behaves more similarly to DLBCL than MALT [33, 35,
42, 44, 45]. Staging of PTL is based on extension from the thyroid gland. Stage 1 disease is
localized to the thyroid gland; stage 2 disease is localized to the thyroid gland but also involves
regional lymph nodes; stage 3 disease involves spread to lymph nodes on both sides of the
diaphragm; stage 4 disease has spread to distant sites of the body [36].
The management of PTL is primary through chemotherapy and radiation; surgery is reserved
for early stage MALT localized to the thyroid gland or for patients suffering from compressive
symptoms [5, 46]. The chemotherapeutic regimen commonly utilized, CHOP, consists of
cyclophosphamide, hydroxydoxorubicin, vincristine, and prednisone [47, 48].
Chai et al. examined 38 patients with PTL, 92% early stage, treated with a combination of
surgery, chemotherapy, radiation, or a combination. Few patients received single modality
therapy, while the majority were treated with multimodality therapy. Treatment outcomes
were followed from 3 to 156 months with the median follow up being 56 months. They reported
a 100% 5-year disease specific survival for MALT lymphoma, 100% for mixed, and 87.5% for
DLBCL [39]. This concurs with previous studies reporting a 96–100% 5-year disease specific
survival for MALT lymphoma, and shows an improvement in survival compared to the
previously reported 71–75% 5-year disease specific survival for DLBCL [35, 36, 49]. Stratifying
survival by stage, a surveillance, epidemiology, and end results (SEER) database study by
Graff Baker reported 86% 5-year disease-specific survival for stage 1 PTL, 81% for stage 2, and
64% for stages 3 and 4 [36].
As overall prognosis is highly dependent on the subtype of primary thyroid lymphoma and
the stage at presentation, the practitioner must have a high suspicion for lymphoma especially
in a patient with a history of Hashimoto’s presenting with enlarging neck mass. Establishing
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a diagnosis with sufficient cell volume to perform flow cytometry is crucial in categorizing the
subtype of lymphoma and quickly beginning treatment with a multidisciplinary team.
5. Medullary thyroid cancer
MTC is a malignancy that arises from the calcitonin producing parafollicular cells and
comprises 3–5% of thyroid malignancies [2, 50]. It is important to note that the parafollicular
c-cells also produce carcinoembryonic antigen (CEA), prostaglandin, and serotonin of which
excess levels could lead to symptoms [10]. Males and females are equally affected, typically
over the age of 50 [51, 52].
The majority of MTC, approximately 75%, occurs in a sporadic fashion and generally are
unilateral and unifocal [50, 52]. The remaining MTC is derived from an autosomal dominant
hereditary pattern associated with the RET proto-oncogene. Hereditary MTC is more likely to
be multifocal and bilateral in nature [53–59]. Thirty percent of MTC affects patients younger
than 50 and can have a familial inheritance pattern including the association with multiple
endocrine neoplasia (MEN) syndromes. MTC in MEN2A is associated with pheochromocy‐
toma and hyperparathyroidism, while MTC associated with MEN2B is associated with
mucosal neuromas, Marfanoid habitus, or pheochromocytoma [53, 54, 60, 61].
Patients commonly present with a painless thyroid nodule that can be accompanied by
palpable cervical adenopathy [50]. Pain, dyspnea, and dysphagia are worrisome symptoms
that can indicate invasion of local structures or compression from mass effect [2]. Symptoms
of serotonin production can also be present such as diarrhea or flushing [50]. Initial regional
spread can be found in the central neck, lateral neck, or superior mediastinum. Fifty percent
of MTC patients have distal metastases on diagnosis, typically involving the mediastinum,
liver, bone, or lung [62].
Diagnosis is based on ultrasound, fine needle aspiration, and appropriate testing of serum
markers. FNA of MTC shows infiltrating neoplastic cells with marked heterogeneity. Occa‐
sionally, amyloid deposits resulting from polymerized calcitonin will be found, strongly
indicative of MTC [63]. Following FNA diagnosis of MTC, patients should have calcitonin and
CEA levels evaluated, as they are both diagnostic and important for surveillance [2]. Calcitonin
strongly correlates with tumor volume and progression while CEA is a predictor of survival.
Often, the doubling of calcitonin can be followed to determine the rate of tumor progression.
A doubling time of greater than 6 months is associated with a 5-year survival of 92% while a
doubling time less than 6 months is associated with a 5-year survival of 25% [64, 65]. CT
imaging of the neck and mediastinum can be pursued to evaluate for radiographic evidence
of spread. As the uptake of fluorodeoxyglucose is low in MTC, PET scanning is not routinely
recommended. However, the use of other radionuclide tracers such as 18F-DOPA can be useful,
as 18F-DOPA has been reported to have a sensitivity of 81%, much greater than FDG for
metastatic disease [66]. To evaluate for metastases, CT of the chest, abdomen, and head is
recommended along with MRI of the liver and brain due to the increased accuracy [50].
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Prior to undertaking treatment, the patient should also be evaluated for RET mutations and
a thorough screening for MEN syndrome should be completed. Genetic testing is becoming
more common with these patients and their families as early detection and treatment of
family members may lead to favorable prognoses. The workup of MEN syndrome includes
evaluation of hyperparathyroidism by checking calcium and parathyroid hormone levels.
More importantly, patients should have a 24-h urine screen for catecholamines and meta‐
nephrines along with an abdominal MRI to evaluate for the presence of a pheochromocyto‐
ma. An undiagnosed or poorly managed pheochromocytoma could result in an
intraoperative catastrophe leading to a significant increase in mortality [2, 50].
Initial treatment of MTC is total thyroidectomy and bilateral central neck dissection. Family
members with MEN2B or MEN 2C are recommended to have a prophylactic total thyroidec‐
tomy [2, 50]. If the patient has positive central neck adenopathy or palpable lateral neck disease,
a neck dissection of levels two through six should be performed along with dissection of the
superior mediastinal lymph nodes on the ipsilateral side or bilaterally if indicated. If the
primary MTC lesion is greater than 1 cm, there can be a greater than 50% chance of occult
metastases to the ipsilateral neck and a lateral neck dissection should be performed in that
scenario as well [67–69]. As MTC is from parafollicular cells, it does not respond to radioactive
iodine therapy [70]. Following surgery, patients should be followed with serial calcitonin and
CEA levels to evaluate for recurrence or persistent disease [69]. External beam radiation can
be considered for resections with positive margins or unresectable tumor [2]. Serum calcitonin
greater than 150 pg/ml signifies residual or metastatic disease [64, 71].
Advanced MTC can be potentially treated with surgery and postoperative radiation, but often
patients with extensive local disease or distal metastases are not surgical candidates. Chemo‐
therapy in MTC, often times involving a combination of doxorubicin, dacarbazine, or cisplatin,
is indicated only in rapidly progressive metastatic disease, but the response rates have not
been reported higher than 20% [72–75]. Currently, molecular therapies targeting kinases of
VEGFR2 and REF are in clinical trials but reserved for a very specific subset of patients given
the adverse risk profile [76]. The overall prognosis of MTC is related to disease stage. Ten-year
survival for all MTC is 61–75%; however, the presence of cervical adenopathy decreases
survival to 45% [70].
MTC can be an aggressive malignancy with limited treatment options. Early intervention and
close surveillance with imaging and serum markers are vital. As this malignancy has the
possibility of being associated with concomitant endocrine maladies and familial inheritance,
a thorough assessment of the patient and family alike can allow for safe treatment and the
prevention of disease progression.
6. Conclusion
Anaplastic thyroid cancer, primary thyroid lymphoma, primary thyroid sarcoma, and
medullary thyroid cancer are all extremely rare malignancies that make up a small portion of
all thyroid malignancies. The literature available for guiding management is often limited as
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the small number of cases precludes adequate investigation in clinical trials. Although these
rare malignancies are not frequently encountered, they have the potential of being aggressive
with poor outcomes if not managed in a timely fashion. Patients with any of the above
malignancies should be encouraged to be vigilant in the care and follow up of these conditions.
Practitioners should make every attempt to rapidly establish a diagnosis for thyroid nodules
and initiate treatment in an expedited fashion while keeping the patients and their families
closely involved in the decision making process.
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